Clinical Trial Update: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]

View source ↗

Summary

Mayo Clinic is conducting a Phase 1 clinical trial evaluating a CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies. The study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Transformed Chronic Lymphocytic Leukemia

Drugs mentioned

• CD19-directed CAR-T cell therapy

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Status: RECRUITING